Vis enkel innførsel

dc.contributor.authorKnappskog, Stianen_US
dc.contributor.authorLeirvaag, Berylen_US
dc.contributor.authorGansmo, Liv Beateen_US
dc.contributor.authorRomundstad, Pålen_US
dc.contributor.authorHveem, Kristianen_US
dc.contributor.authorVatten, Larsen_US
dc.contributor.authorLønning, Per Eysteinen_US
dc.date.accessioned2016-11-30T12:24:45Z
dc.date.available2016-11-30T12:24:45Z
dc.date.issued2016-09-27
dc.PublishedHereditary Cancer in Clinical Practice 2016, 14(1):19eng
dc.identifier.issn1731-2302
dc.identifier.urihttps://hdl.handle.net/1956/13162
dc.description.abstractBackground: While germline CHEK2 mutations have been linked to a moderately elevated cancer risk, to date, a limited number of such mutations have been identified. Recently, we reported a germline nonsense mutation (C283T; R95*), introducing an early stop-codon, in two Norwegian patients diagnosed with locally advanced breast cancer. Both patients were resistant to anthracycline therapy, resembling what has been observed for TP53 mutations. Methods: In the present study, we screened a large population based sample, including 3748 non-cancer individuals and 7081 incident cancer cases (breast cancer, n = 1717; prostate cancer n = 2501, lung cancer n = 1331 and colorectal cancer n = 1532), for the distribution of CHEK2 R95*. Results: We found that 12 individuals (0.11 %) carried the R95* variant: 4 non-cancer individuals (0.11 %), 4 breast cancer cases (0.23 %), and 4 prostate cancer cases (0.16 %). Although the low number of observations precluded formal statistical assessment, our data may indicate an elevated risk for breast (OR: 2.19, 95 % CI: 0.55–8.75) and prostate cancer (OR: 1.5, 95 % CI: 0.36–6.00) associated with CHEK2 R95*. By mining international databanks, we found no individuals carrying the R95* mutation, indicating it to be restricted to the Norwegian population. Conclusion: We provide proof-of-concept that previously unknown CHEK2 germline mutations may be present in certain populations. Notably, germline mutations in tumours are in general missed by contemporary massive parallel sequencing strategies, since tumour mutations are usually filtered against the germline. The fact that the CHEK2 R95* mutation may be associated with resistance to anthracyclines in cancer patients emphasizes its possible clinical importance.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.titlePrevalence of the CHEK2 R95* germline mutationen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2016-10-11T12:09:47Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2016 The Author(s)
dc.identifier.doihttps://doi.org/10.1186/s13053-016-0059-0
dc.identifier.cristin1393999


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY